Promising Early Results For AZ And Daiichi’s Dato-DXd In Breast Cancer – But How Soon Can They File?

Partners Keen To Take On Gilead’s Trodelvy

 
• By Andrew McConaghie
  
China Beijing Ciftis
AZ and Daiichi Sankyo hope that Dato-DXd can follow in the footsteps of their other ADC, Enhertu, and become an oncology blockbuster. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapy Areas